These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18725588)

  • 1. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy?
    Schaumburg H; Herskovitz S
    Neurology; 2008 Aug; 71(9):622-3. PubMed ID: 18725588
    [No Abstract]   [Full Text] [Related]  

  • 2. Cervical MRI of subacute myelo-optico-neuropathy.
    Kimura E; Hirano T; Yamashita S; Hirai T; Uchida Y; Maeda Y; Uchino M
    Spinal Cord; 2011 Feb; 49(2):182-5. PubMed ID: 20548321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subacute myelo-optic neuropathy (SMON). First neuro-pathological report outside Japan.
    Ricoy JR; Ortega A; Cabello A
    J Neurol Sci; 1982 Feb; 53(2):241-51. PubMed ID: 6460092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible nitrous oxide-induced myeloneuropathy with pernicious anemia: case report and literature review.
    Singer MA; Lazaridis C; Nations SP; Wolfe GI
    Muscle Nerve; 2008 Jan; 37(1):125-9. PubMed ID: 17623854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospective study on the side-effects of the clioquinol preparation mexaform with special reference to subacute myelo-optic neuropathy].
    Bezjak B; Breintenfeld V; Schönwald S; Car V; Puskarić-Hamel N; Vrancić J; Hotujac L
    Lijec Vjesn; 1974 Sep; 96(9):553-6. PubMed ID: 4281043
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.
    Konagaya M; Matsumoto A; Takase S; Mizutani T; Sobue G; Konishi T; Hayabara T; Iwashita H; Ujihira T; Miyata K; Matsuoka Y
    J Neurol Sci; 2004 Mar; 218(1-2):85-90. PubMed ID: 14759638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals.
    Tateishi J
    Neuropathology; 2000 Sep; 20 Suppl():S20-4. PubMed ID: 11037182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of myelo-optic neuropathy preceded by abdominal symptoms].
    Massons Cirera J; Zunzunegui Costas J; Titus Alvareda F
    Med Clin (Barc); 1983 Jun; 80(20):894-5. PubMed ID: 6224988
    [No Abstract]   [Full Text] [Related]  

  • 9. [Toward the complete understanding of the pathogenic mechanism of clioquinol-induced subacute myelo-optic neuropathy (SMON)].
    Katsuyama M
    Nihon Yakurigaku Zasshi; 2024; 159(2):78-82. PubMed ID: 38432923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper deficiency myeloneuropathy in a patient with Wilson disease.
    da Silva-Júnior FP; Machado AA; Lucato LT; Cançado EL; Barbosa ER
    Neurology; 2011 May; 76(19):1673-4. PubMed ID: 21555737
    [No Abstract]   [Full Text] [Related]  

  • 11. Diminished skin vasodilator response to local heating in patients with long-standingsubacute myelo-optico-neuropathy.
    Yamanaka Y; Asahina M; Akaogi Y; Koyama Y; Hattori T
    J Neurol Sci; 2007 Sep; 260(1-2):214-8. PubMed ID: 17572442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelo-optic neuropathy induced by clioquinol in animals.
    Tateishi J; Kuroda S; Saito A; Otsuki S
    Lancet; 1971 Dec; 2(7736):1263-4. PubMed ID: 4143622
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible cervical hydromyelia in subacute combined degeneration.
    Canas N; Calado S; Ribeiro C; Vale J
    Neurology; 2005 Aug; 65(3):E7. PubMed ID: 16087892
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary spinal cord neurodegeneration in Leber hereditary optic neuropathy.
    Jaros E; Mahad DJ; Hudson G; Birchall D; Sawcer SJ; Griffiths PG; Sunter J; Compston DA; Perry RH; Chinnery PF
    Neurology; 2007 Jul; 69(2):214-6. PubMed ID: 17620555
    [No Abstract]   [Full Text] [Related]  

  • 15. Tongue strength in patients with subacute myelo-optico-neuropathy.
    Yamashita S; Nakama T; Ueda M; Honda S; Kimura E; Konagaya M; Ando Y
    J Clin Neurosci; 2018 Jan; 47():84-88. PubMed ID: 29054330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The solution structure of the copper clioquinol complex.
    Pushie MJ; Nienaber KH; Summers KL; Cotelesage JJ; Ponomarenko O; Nichol HK; Pickering IJ; George GN
    J Inorg Biochem; 2014 Apr; 133():50-6. PubMed ID: 24503514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal sensory motor neuropathy in copper-deficient Wilson's disease.
    Foubert-Samier A; Kazadi A; Rouanet M; Vital A; Lagueny A; Tison F; Meissner W
    Muscle Nerve; 2009 Aug; 40(2):294-6. PubMed ID: 19609919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery after copper-deficiency myeloneuropathy in Wilson's disease.
    Teodoro T; Neutel D; Lobo P; Geraldo AF; Conceição I; Rosa MM; Albuquerque L; Ferreira JJ
    J Neurol; 2013 Jul; 260(7):1917-8. PubMed ID: 23712800
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.
    Baumgartner G; Gawel MJ; Kaeser HE; Pallis CA; Rose FC; Schaumburg HH; Thomas PK; Wadia NH
    J Neurol Neurosurg Psychiatry; 1979 Dec; 42(12):1073-83. PubMed ID: 230316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelo-optic neuropathy caused by aconitine in rabbit model.
    Kim SH; Kim SD; Kim SY; Kwak JS
    Jpn J Ophthalmol; 1991; 35(4):417-27. PubMed ID: 1668243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.